# Theravance Biopharma share price (Theravance Biopharma, Inc., TBPH)

> Theravance Biopharma, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. TBPH · Healthcare · Biotechnology · data as of 23 September 2026. Page: https://www.sectoralpha.in/us/stocks/tbph

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $17.03 (+21.0% in a year)
- P/E: 16.3× (higher than 71% of the last 4 years)
- Revenue (Jun 2026): $20.7 M (−20.9% on a year ago)
- Profit (Jun 2026): −$5.9 M (−110.8% on a year ago)
- Operating margin: 8.9% (+19.3 points on a year ago)
- ROE: 36%, FY25
- ROIC: −3.7%, against a 5.5% cost of capital: −9.2 points
- Profit that came in as cash: 5%, last 2 years

Biggest thing to watch: the P/E is higher than 71% of its own history, so the multiple has already done part of the work. ## What is the Theravance Biopharma share price? Theravance Biopharma, Inc.'s share price was $17.03 at the close on 23 September 2026. It has been moving sideways for 10 weeks. That is 0.9% below its average price over the last 200 trading days. In the last 52 weeks it traded between $14 and $20, and at that close it sat 50% of the way up from that low. Over the past 13 weeks it has done worse than the S&P 500, and it has been behind for 1 week running. Over the last 10 years the share price moved −27% while the S&P 500 moved +263%, so it is behind the index over that whole period. It was last ahead over 13 weeks in the week of 18 September 2026. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Theravance Biopharma pay? Theravance Biopharma, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Theravance Biopharma on? Theravance Biopharma is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Theravance Biopharma profitable? Theravance Biopharma, Inc. posted a net loss of $5.9 M in the Jun 2026 quarter. Full-year FY25 profit was $106 M. That loss is 28.5% of the quarter's revenue. The same quarter a year earlier earned $54.8 M. 9 of the last 12 reported quarters were loss-making. Jun 2026 profit was −$5.9 M, −110.8% on a year earlier. ## How much revenue does Theravance Biopharma make, and is it growing? Theravance Biopharma, Inc. reported $20.7 M of revenue in the Jun 2026 quarter, −20.9% on the same quarter a year earlier. Over 4 years it has grown 18.1% a year on average. The last full year, FY25, came in at $107 M. The last four reported quarters add to $104 M. FY25 revenue was $107 M, +66.9% on the year before. Recent pace: the last four quarters grew +39.3% on average, against 18.1% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +35.1%, against +29.7% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Theravance Biopharma keep? Theravance Biopharma, Inc.'s operating margin was 8.9% in the Jun 2026 quarter, 19.3 percentage points higher than the same quarter a year ago. Across 5 years it has been between −429.6% and −3.4%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +19.3 percentage points on the year while gross margin changed +17.3 points. So the gain came mostly from the gross margin, which means input costs and prices charged. ## Is Theravance Biopharma's profit turning into cash? Over the last 2 years, 5% of Theravance Biopharma, Inc.'s reported profit came in as cash from its operations, a gap worth watching. In FY25 it brought in $239 M of operating cash against $106 M of profit. After $42.0 K of spending on assets, $238 M was left over as free cash. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Theravance Biopharma's cash go? Theravance Biopharma, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $2.9 M on assets over the last 3 years. Averaged over those years that is 0.9% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $2.9 M over the last 3 years. In short: the cash is going into new capacity, not getting stuck in the daily cycle. The question is whether the new capacity earns. ## What is Theravance Biopharma's P/E ratio, and how does it compare with its own history? Theravance Biopharma, Inc.'s P/E is 16.3×, near the high end of its own history: higher than 71% of past readings. Its usual P/E (the middle reading) is 1.0×, over 4 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 3 years the price moved +23.2% a year; about −55.3% a year came from earnings growth and about +78.5 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. ## Is the Theravance Biopharma business getting better or worse? Theravance Biopharma, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Theravance Biopharma earn on its capital? Theravance Biopharma, Inc. earned a ROE of 36% in FY25. That is up from a low of −32% in FY24. Its return on capital used (ROIC) is 9.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a 98.5% net margin and 0.22× asset turnover (sales divided by assets). Why the return is what it is (FY25): a 98.5% net margin × 0.22× asset turnover × 1.64× leverage (assets divided by equity) ≈ 35.5% on equity. The margin does most of the work; borrowing is a big part of it. The key test, return on capital used minus the cost of capital: −3.7% − 5.5% = −9.2 percentage points. The 5.5% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. ## Does Theravance Biopharma have too much debt? Theravance Biopharma, Inc. has total debt of $38.6 M against shareholder equity of $290 M as of Jun 2026, so its debt is 0.13× its equity, which is very little. Year by year, that ratio went from −1.98 in FY21 to 0.14 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Theravance Biopharma shareholding pattern? 6.3% of Theravance Biopharma, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 3.2 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Theravance Biopharma from balance-sheet trouble? For Theravance Biopharma, Inc., the Z-score is 1.36. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is in the danger zone. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 1.36 is inside the danger zone, so the balance sheet is a real risk. ## How does Theravance Biopharma rank in its industry? There is no score against its industry: Theravance Biopharma, Inc. is not among the largest members shown in this industry comparison for Biotechnology. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Theravance Biopharma compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Theravance Biopharma in size? Theravance Biopharma is the 116th largest of 211 Biotechnology companies on Sector Alpha by market value (scores of 5 November 2026). Just above it: Monte Rosa Therapeutics, Inc., MeiraGTx Holdings plc and Prime Medicine, Inc. Just below it: Pharming Group N.V., Aktis Oncology, Inc. and Ardelyx, Inc. ### Biotechnology companies close in size

1. [Monte Rosa Therapeutics, Inc.](https://www.sectoralpha.in/us/stocks/glue) $923 million
2. [MeiraGTx Holdings plc](https://www.sectoralpha.in/us/stocks/mgtx) $905 million
3. [Prime Medicine, Inc.](https://www.sectoralpha.in/us/stocks/prme) $884 million
4. Theravance Biopharma, Inc. $884 million
5. [Pharming Group N.V.](https://www.sectoralpha.in/us/stocks/phar) $880 million
6. [Aktis Oncology, Inc.](https://www.sectoralpha.in/us/stocks/akts) $845 million
7. [Ardelyx, Inc.](https://www.sectoralpha.in/us/stocks/ardx) $827 million

[All 211 Biotechnology companies, largest first](https://www.sectoralpha.in/us/sectors/biotechnology#all-companies)

### Companies close in size in other industries

1. [USA TODAY Co., Inc.](https://www.sectoralpha.in/us/stocks/tday) $884 million · Publishing
2. [Prime Medicine, Inc.](https://www.sectoralpha.in/us/stocks/prme) $884 million · Biotechnology
3. Theravance Biopharma, Inc. $884 million
4. [Pharming Group N.V.](https://www.sectoralpha.in/us/stocks/phar) $880 million · Biotechnology
5. [Douglas Dynamics, Inc.](https://www.sectoralpha.in/us/stocks/plow) $880 million · Auto Parts

## What else do people ask about Theravance Biopharma? ### What were Theravance Biopharma's latest quarterly results? Theravance Biopharma, Inc. reported revenue of $20.7 M and a net loss of $5.9 M for the Jun 2026 quarter. Revenue fell 20.9% and profit fell 110.8% compared with a year earlier. Earnings per share were −$0.11. The operating margin was 8.9%, 19.3 percentage points higher than a year earlier (as of 23 September 2026). ### What is Theravance Biopharma's market cap? Theravance Biopharma, Inc.'s market capitalisation is $884 M at a stock price of $17.03. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 23 September 2026). ### How is Theravance Biopharma performing? Theravance Biopharma, Inc.'s share price has been moving sideways for 10 weeks. In its latest quarter, revenue fell 20.9% and profit fell 110.8% compared with a year earlier. Over the past 13 weeks it has done worse than the S&P 500, for 1 week running (as of 23 September 2026). ### Will Theravance Biopharma's stock price go up? This page does not forecast Theravance Biopharma, Inc.'s stock price. What it shows instead: the stock price is $17.03, and it has been moving sideways for 10 weeks. Its P/E of 16.3× is higher than 71% of its own last 4 years (as of 23 September 2026). ### Where is Theravance Biopharma in its business cycle? Theravance Biopharma, Inc.'s FY25 operating margin was −3.4%, against a 5-year range of −429.6% to −3.4%: the middle of its own range, neither a peak nor a low. The latest quarter was 8.9%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 23 September 2026). ### What could break the Theravance Biopharma story? Biggest thing to watch: the P/E is higher than 71% of its own history, so the multiple has already done part of the work. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 23 September 2026). ### Is Theravance Biopharma a stock worth studying right now? What the numbers show: Theravance Biopharma, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 23 September 2026). This is research, not advice. We’re not SEBI-registered.